JP2016506391A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506391A5 JP2016506391A5 JP2015546449A JP2015546449A JP2016506391A5 JP 2016506391 A5 JP2016506391 A5 JP 2016506391A5 JP 2015546449 A JP2015546449 A JP 2015546449A JP 2015546449 A JP2015546449 A JP 2015546449A JP 2016506391 A5 JP2016506391 A5 JP 2016506391A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- use according
- subject
- insulin resistance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 40
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 10
- 206010022489 Insulin Resistance Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 7
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- 230000004792 oxidative damage Effects 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010053648 Vascular occlusion Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 208000004608 Ureteral Obstruction Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 208000002177 Cataract Diseases 0.000 claims description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
- 206010013774 Dry eye Diseases 0.000 claims description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010058222 Hypertensive cardiomyopathy Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 206010067125 Liver injury Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000033626 Renal failure acute Diseases 0.000 claims description 2
- 201000007737 Retinal degeneration Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- -1 antibodies Substances 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 229940030600 antihypertensive agent Drugs 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 239000002872 contrast media Substances 0.000 claims description 2
- 150000004696 coordination complex Chemical class 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- 229940012356 eye drops Drugs 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 230000010410 reperfusion Effects 0.000 claims description 2
- 230000004258 retinal degeneration Effects 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 238000000034 method Methods 0.000 description 34
- 230000002265 prevention Effects 0.000 description 6
- 102000049320 CD36 Human genes 0.000 description 4
- 108010045374 CD36 Antigens Proteins 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 208000027032 Renal vascular disease Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 208000037806 kidney injury Diseases 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 208000015670 renal artery disease Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000035873 Ventilator-induced diaphragmatic dysfunction Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 230000012154 norepinephrine uptake Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037050 permeability transition Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261734293P | 2012-12-06 | 2012-12-06 | |
| US61/734,293 | 2012-12-06 | ||
| PCT/US2013/036214 WO2014088631A1 (en) | 2012-12-06 | 2013-04-11 | Peptide therapeutics and methods for using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017146044A Division JP2018021033A (ja) | 2012-12-06 | 2017-07-28 | ペプチド治療薬およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016506391A JP2016506391A (ja) | 2016-03-03 |
| JP2016506391A5 true JP2016506391A5 (enExample) | 2016-06-02 |
Family
ID=49549068
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015546449A Pending JP2016506391A (ja) | 2012-12-06 | 2013-04-11 | ペプチド治療薬およびその使用方法 |
| JP2017146044A Pending JP2018021033A (ja) | 2012-12-06 | 2017-07-28 | ペプチド治療薬およびその使用方法 |
| JP2018208926A Pending JP2019069942A (ja) | 2012-12-06 | 2018-11-06 | ペプチド治療薬およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017146044A Pending JP2018021033A (ja) | 2012-12-06 | 2017-07-28 | ペプチド治療薬およびその使用方法 |
| JP2018208926A Pending JP2019069942A (ja) | 2012-12-06 | 2018-11-06 | ペプチド治療薬およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20130303436A1 (enExample) |
| EP (3) | EP2928562A4 (enExample) |
| JP (3) | JP2016506391A (enExample) |
| CN (1) | CN104994912A (enExample) |
| CA (1) | CA2894182A1 (enExample) |
| HK (1) | HK1215934A1 (enExample) |
| WO (1) | WO2014088631A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015005102A (es) * | 2012-10-22 | 2016-02-09 | Stealth Peptides Int Inc | Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo. |
| US10772554B2 (en) * | 2013-09-04 | 2020-09-15 | Joseph Michael Lawless Kelly | Methods and systems for the detection of disease |
| US9895410B2 (en) * | 2013-12-12 | 2018-02-20 | Cornell University | Methods for preventing and treating oral cancers |
| SG10201805039UA (en) * | 2013-12-13 | 2018-07-30 | Medimmune Ltd | Protease resistant peptides |
| EP3082838A4 (en) * | 2013-12-16 | 2017-07-26 | Cornell University | Methods and compositions for treating and preventing cognitive dysfunction |
| CN112457368A (zh) * | 2013-12-27 | 2021-03-09 | 康德生物医疗技术公司 | 药学相关的芳香族阳离子肽 |
| CA2942143A1 (en) * | 2014-03-03 | 2015-09-11 | Stealth Biotherapeutics Corp | Pharmaceutically relevant aromatic-cationic peptides and methods of generating the same |
| WO2015183970A1 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including flavonoid and uses thereof |
| US10576124B2 (en) * | 2014-05-28 | 2020-03-03 | Stealth Biotherapeutics Corp | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof |
| WO2015183985A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including naphthoquinones and uses thereof |
| US20170182117A1 (en) * | 2014-05-28 | 2017-06-29 | Stealth Biotherapeutics Corp | Therapeutic compositions including therapeutic small molecules and uses thereof |
| WO2015183963A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
| WO2015183984A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including tocopherol and uses thereof |
| US10627392B2 (en) | 2014-06-17 | 2020-04-21 | Stealth Biotherapeutics Corp | Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening |
| EP3182989B1 (en) | 2014-08-21 | 2021-04-14 | Stealth Biotherapeutics Corp | Peptide d-arg-2',6'-dmt-lys-phe-nh2 for treating alport syndrome |
| ES2630106T3 (es) * | 2014-10-07 | 2017-08-18 | Cyprumed Gmbh | Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos |
| RU2711913C2 (ru) | 2014-11-07 | 2020-01-24 | Дзе Джонс Хопкинс Юниверсити | Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом |
| US20170315135A1 (en) * | 2014-11-11 | 2017-11-02 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having retinits pigmentosa |
| US11268964B2 (en) * | 2014-11-11 | 2022-03-08 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having diseases of the eye |
| CA2978905A1 (en) | 2015-03-06 | 2016-09-15 | Stealth Biotherapeutics Corp | Processes for preparing pharmaceutically relevant peptides |
| WO2016190852A1 (en) * | 2015-05-26 | 2016-12-01 | Stealth Peptides International, Inc. | Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof |
| WO2016195663A1 (en) * | 2015-06-02 | 2016-12-08 | Stealth Peptides International, Inc. | Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof |
| TWI726889B (zh) * | 2015-06-10 | 2021-05-11 | 英商梅迪繆思有限公司 | 蛋白酶抗性之脂化肽 |
| PL3393496T3 (pl) | 2015-12-23 | 2024-04-22 | The Johns Hopkins University | Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych |
| AU2017249218B2 (en) | 2016-04-11 | 2020-08-27 | Arcuate Therapeutics, Inc. | Chiral peptides |
| CN105987839B (zh) * | 2016-06-03 | 2018-09-28 | 浙江世纪康大医疗科技股份有限公司 | 一种edta-柠檬酸抗原修复液 |
| CN105987840B (zh) * | 2016-06-03 | 2018-09-28 | 浙江世纪康大医疗科技股份有限公司 | 一种柠檬酸抗原修复液 |
| CN109789094A (zh) * | 2016-06-03 | 2019-05-21 | Jt药品公司 | κ-阿片类受体激动剂的持续释放组合物 |
| CN107042067B (zh) * | 2017-05-24 | 2019-11-08 | 天津大学 | 聚硅氧烷-金属有机框架材料杂化渗透蒸发复合膜及其制备与应用 |
| TWI714862B (zh) * | 2017-06-19 | 2021-01-01 | 大陸商深圳瑞健生命科學硏究院有限公司 | 一種調控glp-1/glp-1r的方法和藥物 |
| EP3443980A1 (en) * | 2017-08-15 | 2019-02-20 | Ciliocure Limited | Compound for the treatment of patients with leptin-resistant obesity, bardet-biedl syndrome and other ciliopathies |
| CN111386255B (zh) | 2017-09-20 | 2021-11-23 | 纳崔泰制药有限公司 | 用于制备n-乙酰基半胱氨酸酰胺及其衍生物的方法 |
| US11091433B2 (en) | 2017-09-20 | 2021-08-17 | Nacuity Pharmaceutials, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
| US11548851B2 (en) | 2017-09-20 | 2023-01-10 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide and derivatives thereof |
| US20190135741A1 (en) | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| WO2019201333A1 (zh) * | 2018-04-19 | 2019-10-24 | 杭州先为达生物科技有限公司 | Glp-1衍生物及其治疗用途 |
| US11766413B2 (en) | 2019-01-11 | 2023-09-26 | Nacuity Pharmaceuticals, Inc. | Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA) |
| US12458608B2 (en) | 2019-01-11 | 2025-11-04 | Nacuity Pharmaceuticals, Inc. | N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement |
| AU2020316449A1 (en) * | 2019-07-24 | 2022-02-10 | Stealth Biotherapeutics Inc. | The peptidomimetic compound (R)-2-amino-N-((S)-L-(((S)-5-amino-L-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-l-oxopropan-2-yl)-5-guanidinopentanamide in the treatment of neurodegenerative diseases |
| US12383547B2 (en) | 2020-07-01 | 2025-08-12 | Vanderbilt University | Methods of treatment for a kidney disease |
| KR102503914B1 (ko) * | 2020-09-01 | 2023-02-24 | 인제대학교 산학협력단 | 황반변성 세포모델의 제조방법 |
| KR20220050822A (ko) * | 2020-10-16 | 2022-04-25 | 한미약품 주식회사 | 글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 루푸스-관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN112618966B (zh) * | 2020-12-18 | 2023-07-28 | 北京宏强富瑞技术有限公司 | 一种多波长激光针刺仪 |
| CN113421648B (zh) * | 2021-06-21 | 2024-04-23 | 中国科学院北京基因组研究所(国家生物信息中心) | 一种用于预测射血分数保留型心衰风险的模型 |
| CN113588375B (zh) * | 2021-08-20 | 2023-09-29 | 中科光华(西安)智能生物科技有限公司 | 一种高稳定性骨及骨肿瘤组织微阵列芯片及其制备方法 |
| CN114480449A (zh) * | 2022-03-17 | 2022-05-13 | 天津医科大学总医院 | 布拉氏酵母菌CNCMI-745衍生蛋白Trx2及其在制备防治腹泻药物中的应用 |
| CN114949184A (zh) * | 2022-05-13 | 2022-08-30 | 华中科技大学同济医学院附属同济医院 | Glp-1代谢物在制备减轻急性肾损伤药物中的用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| CA2400628A1 (en) | 2000-03-09 | 2001-09-13 | Genzyme Corporation | Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| AU2002256092C1 (en) | 2001-04-05 | 2009-10-15 | Collagenex Pharmaceuticals, Inc. | Controlled delivery of tetracycline compounds and tetracycline derivatives |
| ATE408414T1 (de) * | 2001-07-31 | 2008-10-15 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
| EP1701731A4 (en) | 2003-12-12 | 2009-08-05 | Einstein Coll Med | GLP-1 (9-36) METHOD AND COMPOSITIONS |
| US20090202497A1 (en) * | 2005-08-23 | 2009-08-13 | The General Hospital Corporation | Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes |
| WO2009040019A2 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| PL2252312T3 (pl) * | 2008-02-07 | 2014-10-31 | Univ Cornell | Sposoby zapobiegania lub leczenia insulinooporności |
| WO2010054326A2 (en) | 2008-11-07 | 2010-05-14 | The General Hospital Corporation | C-terminal fragments of glucagon-like peptide-1 (glp-1) |
| CN105031605A (zh) * | 2009-08-12 | 2015-11-11 | 康奈尔大学 | 预防或治疗代谢综合症的方法 |
| EP3560508A1 (en) * | 2010-03-15 | 2019-10-30 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| CN102614514B (zh) * | 2011-01-26 | 2014-12-10 | 王永祥 | Glp-1受体激动剂用于治疗疼痛 |
-
2013
- 2013-04-11 WO PCT/US2013/036214 patent/WO2014088631A1/en not_active Ceased
- 2013-04-11 EP EP13861220.5A patent/EP2928562A4/en not_active Withdrawn
- 2013-04-11 HK HK16103877.4A patent/HK1215934A1/zh unknown
- 2013-04-11 EP EP18188071.7A patent/EP3459598A1/en not_active Withdrawn
- 2013-04-11 CA CA2894182A patent/CA2894182A1/en not_active Abandoned
- 2013-04-11 US US13/861,226 patent/US20130303436A1/en not_active Abandoned
- 2013-04-11 JP JP2015546449A patent/JP2016506391A/ja active Pending
- 2013-04-11 EP EP17184720.5A patent/EP3287172A1/en not_active Withdrawn
- 2013-04-11 CN CN201380072485.9A patent/CN104994912A/zh active Pending
-
2015
- 2015-04-27 US US14/697,321 patent/US20160101158A1/en not_active Abandoned
-
2017
- 2017-07-28 JP JP2017146044A patent/JP2018021033A/ja active Pending
- 2017-12-21 US US15/850,092 patent/US20180344814A1/en not_active Abandoned
-
2018
- 2018-11-06 JP JP2018208926A patent/JP2019069942A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506391A5 (enExample) | ||
| KR102412997B1 (ko) | 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법 | |
| JP2019507781A5 (enExample) | ||
| JP2007503469A (ja) | アミロイド症およびそれに関連した疾患を改善するための作用物質としてのｒａｇｅアンタゴニスト | |
| AU2004298393A1 (en) | Copper antagonist compounds | |
| CN104869993A (zh) | 治疗阿尔茨海默病及相关疾病的组合疗法 | |
| WO2011028794A2 (en) | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist | |
| AU2019214557A1 (en) | Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof | |
| US20240415973A1 (en) | Uses of hyaluronan conjugates | |
| CN112351975B (zh) | 过氧化物酶体增殖物活化受体α的激动剂和使用方法 | |
| JP2025161811A (ja) | タウオパチーを処置するためのペプチド組成物及び方法 | |
| JP7702883B2 (ja) | 神経変性疾患、好ましくはアルツハイマー病を治療するための２－フェニル－６－（１ｈ－イミダゾール－１－イル）キナゾリンの使用 | |
| DE69508551T2 (de) | Verwendung von L-Carnitin und Derivaten zur Verringerung der Toxizität von Cyclosporin-A und anderer Immunosuppressiva | |
| US20070213366A1 (en) | Treatment of Synucleinopathies | |
| CN113546082B (zh) | 特拉匹韦在制备治疗缺血/再灌注损伤的药物及细胞保护药物中的应用 | |
| PH12017501112A1 (en) | Synthetic apelin fatty acid conjugates with improved half-life | |
| CN113975276B (zh) | 考比替尼在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用 | |
| US20220062255A1 (en) | Treatment of neurodegenerative eye disease using pridopidine | |
| US20230338348A1 (en) | Renin-angiotensin system (ras) modulators for treatment of viral infections, pharmaceutical compositions including the same, and methods of treating using the same | |
| CA3185939A1 (en) | N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease | |
| JP2022529742A (ja) | 神経修復方法 | |
| CN115212194A (zh) | 纳多洛尔在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用 | |
| JP2025539186A (ja) | トラミプロセートを用いて神経変性障害を治療する方法 | |
| US20210059984A1 (en) | Method and composition for reversing cognitive impairments and loss using sglt2 inhibitors | |
| WO2023214317A1 (en) | Relative undersupply of an amyloid beta aggregation inhibitor for improved detoxifying effects |